3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
4
Unknown
1
Suspended
1
Recruiting
1
Not yet recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
1
Leukemia
1
Interventions
Injections
39
Carboplatin
33
Capecitabine
24
Paclitaxel
23
Cisplatin
23
Docetaxel
22
pembrolizumab
21
Oxaliplatin
21
Gemcitabine
21
Bevacizumab
19
Pemetrexed
18
Fluorouracil
13
Irinotecan
12
Cyclophosphamide
11
osimertinib
9
Nivolumab
9
Dexamethasone
8
Topotecan
7
Leucovorin
7
130-nm albumin-bound paclitaxel
7
venetoclax
6
toripalimab
6
tislelizumab
6
regorafenib
6
lenvatinib
6
fludarabine
6
Doxorubicin
6
Cetuximab
6
daratumumab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
INDUSTRY
×
Arsenic Trioxide
×
Clear all
NCT07296445
2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3
Not yet recruiting
120 enrolled